Introduction {#Sec1}
============

In August 2007, a panel of neuroendocrinologists from Latin America, the United States of America and the United Kingdom convened in Mexico City to discuss the diagnosis, treatment and follow-up of patients with acromegaly, with a specific focus on Latin America. One of the greatest challenges in providing consensus recommendations in this region is the diversity in this large population of more than 550 million. Furthermore, a range of management approaches may not be available for many patients with acromegaly and the feasibility and cost should be considered in the implementation of local guidelines. Therefore, this meeting was conducted with the aim of providing recommendations for the management of patients with acromegaly in Latin America, and this review highlights the main conclusions reached during this meeting.

Diagnostic criteria {#Sec2}
===================

The panel discussed the criteria used to make a diagnosis of acromegaly and the clinical approaches in cases where a discrepancy between growth hormone (GH) and insulin-like growth factor-1 (IGF-1) measurements are seen. According to the diagnostic criteria proposed at the Cortina consensus, a random GH level lower than 0.4 μg/l and an IGF-1 level within the age- and sex-matched normal range excludes the diagnosis of acromegaly in a patient with no other concurrent illness \[[@CR1]\]. If there is clinical suspicion of acromegaly and either of these levels are not achieved, an oral glucose tolerance test (OGTT) should be performed with 75 g of oral glucose, with subsequent measurements of glucose and GH every 30 min over 2 h; a fall in GH level to ≤1 μg/l and a normal IGF-1 level excludes the diagnosis of acromegaly. The group acknowledged the fact that with the currently used ultrasensitive GH assays, a normal GH suppression by glucose is considerably below 1 μg/l and speculated about the appropriateness of lowering the cutoff to 0.6 μg/l.

Despite the advances in biochemical assays and the definition of cutoff levels for both GH and IGF-1, major limitations in the diagnostic assessment of acromegaly still exist \[[@CR2]\]. Several factors make the biochemical diagnosis of acromegaly challenging, including the pulsatile nature of GH secretion, the sensitivity of GH secretion to sleep, and changes in the secretion of the hormone according to the age and nutritional status of the patient \[[@CR3]\]. Assessment of GH and IGF-1 levels are also made difficult by the lack of uniformity in reference standards and analysis \[[@CR4]\], which result in poor reproducibility and wide variation, in particular for IGF-1 \[[@CR5]--[@CR7]\], and make the diagnosis of acromegaly more challenging. Indeed, several authors have found an overlap between the biochemical results in healthy volunteers and in patients with acromegaly if the criterion of a GH nadir of \<1 μg/l during an OGTT was used \[[@CR8], [@CR9]\].

Given the difficulties in assessing GH and IGF-1 levels, the panel recommended that random GH levels should not be used as a diagnostic tool in acromegaly. Ideally, each laboratory should attempt to standardize age- and sex-matched IGF-1 reference values and establish its own cutoff point. Also, an attempt should be made to certify assays with appropriate biological standards. Notably, even if IGF-1 levels are very high and the clinical picture of acromegaly is clear, GH evaluation during OGTT at diagnosis could be useful, since follow-up management should be taken into consideration. Furthermore, the panel supported the use of an OGTT (using a GH nadir of \<1 μg/l) in patients where there was a discrepancy between IGF-1 levels and the clinical picture. The panel also highlighted that extreme caution should be exercised when employing this test in patients exhibiting glucose intolerance.

First-line therapy {#Sec3}
==================

The panel addressed the issue of when treatment with somatostatin analogues or surgery should be considered. Generally, surgery is indicated for GH-secreting microadenomas, resectable macroadenomas and for decompression of vital structures, particularly the optic tracts \[[@CR3]\]. While cure rates with surgical resection can be as high as 90% in patients with a microadenoma and approximately 50% in patients harboring a macroadenoma, they are lower if the adenoma is invasive \[[@CR10], [@CR11]\]. Despite the known benefits of transsphenoidal resection by experienced surgeons for small pituitary adenomas \[[@CR12]\], patients with larger adenomas (e.g. \>20 mm) and a preoperative GH level greater than 50 μg/l may also require medical and, sometimes, radiation therapy to control GH hypersecretion \[[@CR10], [@CR13]\]. Many patients with acromegaly in Latin America present with large, often inoperable tumors that are not confined to the sella turcica and therefore cannot be cured by surgery alone.

First-line medical therapy has improved over the last decade, and first-line therapy with somatostatin analogues is now considered a viable alternative to surgery in selected patients \[[@CR14]\]. Success rates for octreotide LAR as first-line therapy for acromegaly have been reported to range from 40 to 80% for the achievement of a 'safe' GH level of 2--2.5 μg/l, and from 30 to 65% for the normalization of IGF-1 \[[@CR15], [@CR16]\]. Although there are fewer reported studies concerning lanreotide Autogel as first-line therapy for acromegaly, a recent study in which 26 newly diagnosed patients were treated with lanreotide Autogel for 12 months found that 58% of patients achieved a GH level ≤1.9 μg/l, and 58% of patients had normalized IGF-1 \[[@CR17]\]. In addition to biochemical control, first-line therapy with octreotide LAR has been shown to significantly reduce tumor size in approximately 80% of patients \[[@CR18], [@CR19]\], and recent studies suggest octreotide LAR can also provide long-term biochemical and tumor volumetric control \[[@CR20], [@CR21]\]. Moreover, a recent prospective trial including patients from Latin America has suggested that octreotide LAR represents a viable alternative to surgery for the primary treatment of acromegaly \[[@CR16]\].

Although the panel advocated the use of first-line medical therapy in patients with acromegaly, they acknowledged that access to somatostatin analogues is a key issue in Latin America, as treatment is not always subsidized by government agencies. However, this situation varies not only between countries but also within countries. Therefore, health economic analyses are warranted in this region. Physicians in Latin America should tailor appropriate treatments or combinations for each patient based on the clinical presentation and availability of resources (Fig. [1](#Fig1){ref-type="fig"}). As a general rule, however, the panel recommended that tumor resection performed by an experienced pituitary neurosurgeon should be the first option in patients with a microadenoma or a resectable macroadenoma, as well as in patients with an invasive macroadenoma and visual field defects. Initial surgical therapy could also be indicated for some patients with large invasive tumors to reduce the tumor mass (debulking) and, consequently, reduce GH and IGF-1 levels (albeit without achieving normalization) for the following reasons: (a) unavailability of somatostatin analogues (which is a reality in some countries in Latin America) and; (b) improve the response to medical treatment \[[@CR22], [@CR23]\] and radiotherapy \[[@CR24]\].Fig. 1Suggested algorithm for choosing first-line therapy in Latin American patients with newly diagnosed acromegaly

First-line medical therapy should be indicated for patients who are not willing to undergo, or are not fit for surgery, as well as in those whose tumor has invaded the cavernous sinus or in whom surgical debulking is not feasible. For cases not falling within the above categories, judgment is required to indicate the first-line therapy, taking into account the local experience and availability of resources.

Management and optimization of treatment with somatostatin analogues {#Sec4}
====================================================================

There is now convincing evidence that octreotide LAR is a well-tolerated and effective medical therapy for patients with acromegaly \[[@CR16], [@CR21], [@CR25]--[@CR28]\]. The panel discussed the dose that should be used and how this dose should be modified in clinical practice. Although an acute test dose of subcutaneous octreotide is used in some centers, \[[@CR29]\] the panel agreed that this acute test is generally not predictive of a long-term response to octreotide LAR. Early dose-finding studies of octreotide LAR suggested that one injection of either the 20 or 30 mg dose may provide biochemical control of the disease for up to 4 and 6 weeks, respectively \[[@CR27], [@CR30]\]. More recently, it has been suggested that the variability in individual patient responses to depot somatostatin analogues requires individual dose titration and careful assessment of the optimal dose and injection interval \[[@CR31]--[@CR34]\]. Therefore, it is recommended that patients initiate treatment with octreotide LAR 20 mg every 28 days, with evaluation of biochemical control after 3 or 6 months. For those patients with uncontrolled disease after 3--6 months, the dose should be increased to 30 mg every 28 days. The maximum dose of octreotide LAR used in clinical practice is typically 30 or 40 mg every 4 weeks. Despite limited data on the efficacy of the 40 mg dose among patients not responding to the 30 mg dose, some studies have suggested that increasing the dose of octreotide LAR to 40 mg in these patients may result in enhanced suppression of GH and IGF-1 levels without additional toxicity \[[@CR33], [@CR35]\].

In patients well controlled with octreotide LAR (normal serum GH and IGF-1 levels), two different approaches may be considered. The first is to reduce the dose (from 30 to 20 mg, or from 20 to 10 mg, for example), keeping the same dose interval \[[@CR36]\]. Secondly, increasing the injection interval of octreotide LAR treatment from 4 to 6 weeks may be feasible \[[@CR37]\].

Similarly, lanreotide Autogel may be initiated at a dose of 90 mg every 28 days, and then titrated up to 120 mg or down to 60 mg every 28 days after 3--6 months depending on the level of biochemical control. There is also some evidence that the dose interval of lanreotide Autogel may be extended in patients with biochemical control \[[@CR38]\].

Despite the controversy associated with the monitoring of patients treated with somatostatin analogue therapy, an algorithm recently proposed by a group in Oxford, UK used GH levels of 2.5 μg/l as an indication of biochemical control \[[@CR32]\]. There are many reports stating that both GH and/or IGF-1 are important for achieving disease control \[[@CR39]--[@CR43]\] and, as discussed, there are known limitations regarding their measurement \[[@CR3]\]. Because of these limitations, the most reliable evaluation to confirm disease control would be to assess both GH and IGF-1 values \[[@CR44]\]. Therefore, the panel recommended using IGF-1 levels for decisions regarding the appropriateness of dose and injection interval, GH levels (either basal or an average of 5--6 h consecutive measurements) to monitor medical therapy, and GH levels after OGTT to assess cure or disease control after surgery (and when IGF-1 values and the clinical picture are discrepant). Although a 3-month interval for biochemical assessment was considered appropriate in most cases, the panel emphasized that IGF-1 levels may take longer to return to normal than GH levels.

Combining and changing medical therapy {#Sec5}
======================================

The next issue addressed by the panel was uncontrolled disease in patients who had received optimal doses of somatostatin analogues and maximal surgical debulking. Approximately one-third of patients with acromegaly treated with somatostatin analogues for prolonged periods of time do not achieve safe levels of GH or a normalization of serum IGF-1 levels, and such lack of control is thought to be related to the type and density of somatostatin receptor subtype (sst) expression in the tumor \[[@CR45]\]. Therefore, the panel recommendations below (Fig. [2](#Fig2){ref-type="fig"}) are applicable to patients whose disease remains uncontrolled by maximal somatostatin analogue therapy equivalent to monthly octreotide LAR doses of 30 or 40 mg.Fig. 2Suggested treatment algorithm for Latin American patients with acromegaly and no disease control after maximal surgical debulking and somatostatin analogue therapy. \* Because pegvisomant is not available in all Latin American countries, radiotherapy might be considered as an additional treatment option for patients not controlled after maximal doses of somatostatin analogues and/or cabergoline

Cabergoline is a dopamine agonist with a potent and long-lasting action, as well as an acceptable safety profile, when compared with bromocriptine \[[@CR46]\]. Studies of single-agent cabergoline administered as weekly doses ranging from 1.0 to 3.5 mg, have demonstrated that cabergoline is effective in patients with and without prolactin cosecretion \[[@CR46], [@CR47]\]. However, it is currently unclear whether patients whose disease is resistant to somatostatin analogue therapy should receive cabergoline as a single agent or in combination with a somatostatin analogue. Despite the preliminary evidence of prolonged biochemical control in patients responding to somatostatin analogues in whom therapy is withdrawn \[[@CR48], [@CR49]\], there is anecdotal evidence of a worsening in biochemical parameters when somatostatin analogue therapy is withdrawn in patients whose disease is resistant to somatostatin analogues. Furthermore, studies using fluorescent resonance energy transfer techniques have demonstrated heterodimerization of somatostatin and dopamine receptors, providing a biological rationale for combination therapy trials \[[@CR50]\]. In studies combining a somatostatin analogue with cabergoline, 42--50% of patients achieved normal IGF-1 levels; in addition, these studies have suggested that such responses do not correlate with serum levels or tissue expression of prolactin \[[@CR51]--[@CR53]\]. Although cabergoline is considered an attractive agent for combination therapy with octreotide LAR in patients with acromegaly in Latin America, at high doses there is an increased risk of cardiac valvular abnormalities \[[@CR54], [@CR55]\]. Patients with acromegaly treated with cabergoline should therefore undergo periodic echocardiographic monitoring.

Pegvisomant, a GH receptor antagonist, represents a further addition to the medical arsenal against acromegaly \[[@CR56]\]. Among patients treated primarily with surgery followed by medical therapy and/or radiation therapy, daily administration of pegvisomant has been shown to normalize IGF-1 and provide clinical control of acromegaly in a large number of patients \[[@CR57]\]. In addition, pegvisomant has shown activity among patients whose disease was not adequately controlled by somatostatin analogue therapy \[[@CR58], [@CR59]\]. The major disadvantages of pegvisomant are its high cost, the fact that it does not act directly on the cause of the disease (the pituitary tumor) and the increased risk of elevated liver transaminase levels. Feenstra et al. \[[@CR60]\] assessed the combination of a somatostatin analogue once monthly and pegvisomant once weekly in 26 patients with active acromegaly and concluded that pegvisomant was effective and could significantly reduce the costs of medical treatment for acromegaly (in comparison to monotherapy with pegvisomant) in a proportion of patients whose disease is not fully controlled by somatostatin analogue therapy. The feasibility of widely implementing such a strategy in patients with acromegaly in Latin America remains unknown, although pegvisomant should be considered in selected cases when resources are available. Finally, other medical options for somatostatin analogue-resistant acromegaly may become available in the near future, including agents with multiple sst activity (such as pasireotide \[SOM230\] which has high affinity for sst~1,2,3~ and sst~5~) \[[@CR61]\], agents with selective affinity for sst~2~ and sst~5~ (such as BIM-23244) \[[@CR62]\], and chimeric somatostatin-dopamine receptor agonists (such as BIM-23A387) \[[@CR63]\].

Patient follow-up after surgical resection {#Sec6}
==========================================

The panel discussion focused on the types of, and frequency with which, laboratory and imaging studies should be carried out after surgery with curative intent during follow-up. Currently, there is considerable controversy surrounding this issue, despite the availability of published guidelines regarding postoperative follow-up \[[@CR1], [@CR64]\]. From a biochemical perspective, patient classification into 'active disease' and 'inactive disease' categories may be more appropriate than the use of terms such as 'cure', 'remission', and 'persistence' of the disease. However, it is currently unclear whether patient categorization based on early evaluation, e.g. between 1 and 3 months postoperatively, is of value, as a study in Mexico found that nearly 30% of patients changed their initial category during follow-up \[[@CR65]\]. Also, it is currently uncertain whether patients with normal IGF-1 levels and inadequate GH suppression after an OGTT are at higher risk for recurrent disease activity \[[@CR66]\].

With regard to the classification of active versus inactive disease, the panel recommended assessing patients for 3 months postoperatively, using IGF-1 and GH levels as the main indicator of disease control, as although IGF-1 levels usually stabilize within 3 months after surgery, on rare occasions this may take up to 12 months \[[@CR64]\]. Measurement of GH levels after an OGGT should be reserved for cases where there is some uncertainty, and discordant biochemical results may help tailor the interval of follow-up, which should also be dictated by patient convenience. As a general rule, follow-up during the first year should be performed every 3--6 months, and at least a yearly follow-up is indicated during the first 3 years, but patients should be monitored for life. In addition, lifelong evaluation is recommended for most patients with acromegaly and inactive disease, since recurrences as late as 10--15 years post surgery have been reported \[[@CR67], [@CR68]\]. Magnetic resonance imaging should be carried out 6--12 months after surgery, and repeated only when the results of clinical and biochemical evaluation during follow-up suggest a recurrence, given that this approach appears safe in patients with adequate biochemical control of acromegaly \[[@CR69]\].

The role of radiotherapy {#Sec7}
========================

In the past, radiotherapy has played an important role in the management of patients with acromegaly. In fact, despite some controversy regarding its efficacy and safety, it is still used in some centers, particularly in Latin America, because of its low cost. Although the introduction of effective medical treatment for acromegaly has reduced the interest in radiotherapy, this is often the only available option. So rather than disqualifying radiotherapy, the panel reviewed the available data regarding its performance as a therapeutic tool in acromegaly. Although the efficacy of radiotherapy has been questioned by some studies \[[@CR70], [@CR71]\], a retrospective study by the UK National Acromegaly Register involving 884 patients, 111 of whom had IGF-1 levels assessed on follow-up, found a steady increase in the proportion of patients achieving normalization of IGF-1 levels: 38% at 2 years, 50% at 5 years, and 56% at 15 years \[[@CR72]\]. However, there are known adverse events associated with radiotherapy in patients with acromegaly, including visual loss or deterioration, brain necrosis and vascular complications, secondary tumor formation, hypopituitarism, and neuropsychological damage. It is noteworthy that these adverse effects are minimized when using modern techniques of pituitary irradiation, such as the gamma knife. Therefore, the panel recommendation was to consider radiotherapy for patients with acromegaly who have persistently active disease after pituitary surgery and fully optimized medical therapy (Fig. [2](#Fig2){ref-type="fig"}) and for those operated, uncontrolled patients who have no access to somatostatin analogues. The specific type of radiotherapy, including its modality and schedule, should be guided by local availability and expertise.

Concluding remarks {#Sec8}
==================

The treatment of patients with acromegaly has undergone profound changes in the past decade, largely because of the introduction of effective medical interventions that may be used as first-line therapy in selected cases. Although surgical resection remains the mainstay of therapy for small and potentially resectable pituitary macroadenomas, medical interventions represent a valuable adjunct to the therapeutic arsenal. Radiotherapy may be indicated in selected cases when no disease control is achieved despite optimal surgical debulking and medical therapy, when there is no access to somatostatin analogues, or cost considerations are paramount. Local issues of cost, availability and expertise of neurosurgeons will dictate treatment choice, which should also be tailored according to patient preferences and characteristics. In addition, laboratory evaluation plays an important role in the diagnosis and management of patients with acromegaly, and constant improvements and standardizations of age- and sex-matched reference values are required by local institutions. Finally, physicians in Latin America should adapt their clinical management of patients with acromegaly to the available diagnostic tools and therapeutic options, in order to achieve the best treatment outcome.
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